Cargando…

BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center

BACKGROUND: To investigate Pfizer-BioNTech 162b2 mRNA COVID-19 vaccine (BNT162b2) immunization-related myocarditis and describe the risk factors for consequent hospitalization in the pediatric intensive care unit (PICU) in children between 12 and 18 years. METHODS: Children and adolescents 12 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yen, Chen-Wei, Lee, Jung, Chang, Ya-Ting, Lee, En-Pei, Wu, Chang-Teng, Chang, Yi-Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205643/ https://www.ncbi.nlm.nih.gov/pubmed/37302919 http://dx.doi.org/10.1016/j.pedneo.2023.01.005

Ejemplares similares

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Myocarditis after BNT162b2 vaccination in a healthy male
por: Watkins, Kevin, et al.
Publicado: (2021)

The Peripheral Immune Landscape in a Patient with Myocarditis after the Administration of BNT162b2 mRNA Vaccine
por: Yoon, Bo Kyung, et al.
Publicado: (2022)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
por: Katoto, Patrick D. M. C., et al.
Publicado: (2023)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
por: Lam, Chi-Yan, et al.
Publicado: (2023)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
por: Ab Rahman, Norazida, et al.
Publicado: (2023)

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
por: Bautista García, Javier, et al.
Publicado: (2021)

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19
por: Cueva-Recalde, Juan F., et al.
Publicado: (2023)

Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
por: Kim, Hyeonhui, et al.
Publicado: (2023)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose
por: Miqdad, Mohammed A, et al.
Publicado: (2021)

Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine
por: Fosch, Xavier, et al.
Publicado: (2022)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

Giant cell myocarditis after first dose of BNT162b2 – a case report
por: Hirsch, Valentin G., et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19
por: Kang, Kyusik, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report
por: Lin, Tzu-Chien, et al.
Publicado: (2023)

Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
por: Bader, Guy, et al.
Publicado: (2023)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Systems biological assessment of human immunity to BNT162b2 mRNA vaccination
por: Arunachalam, Prabhu S., et al.
Publicado: (2021)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
por: Ahmed, Sirwan Khalid
Publicado: (2022)

CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine
por: Amir, Gabriel, et al.
Publicado: (2022)

Single-cell sequencing of PBMC characterizes the altered transcriptomic landscape of classical monocytes in BNT162b2-induced myocarditis
por: Hwang, Nahee, et al.
Publicado: (2022)

A case of BNT162b2 COVID‐19 vaccine‐associated fulminant myocarditis in a very elderly woman
por: Otsuka, Kaishi, et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada
por: Buchan, Sarah A., et al.
Publicado: (2023)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
por: Lin, Ting-Yu, et al.
Publicado: (2022)

Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings
por: Choi, Sangjoon, et al.
Publicado: (2021)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7p7fkg4lv6qa8kispvee9pu3q6